Qinchen Gu,1,2 Chen Zhang,3 Zhimin Lin,4 Yiting Fu,5 Chen Li,6,7 Zhenhua Ying2,8,9 

1The Second School of Clinical Medicine, Zhejiang Chinese Medical University, Zhejiang, 310014, People’s Republic of China; 2Department of Rheumatology and Immunology, Center for General Practice Medicine, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital, Hangzhou Medical College), Zhejiang, 310014, People’s Republic of China; 3Department of Rheumatology, Dongfang Hospital Beijing University of Chinese Medicine, Beijing, People’s Republic of China; 4Third Affiliated Hospital, Beijing University of Chinese Medicine, Beijing, People’s Republic of China; 5Beijing University of Chinese Medicine, Beijing, People’s Republic of China; 6Department of Dermatology, Tianjin Institute of Integrative Dermatology, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital, Tianjin, People’s Republic of China; 7Department of Rheumatology, Fangshan Hospital, Beijing University of Chinese Medicine, Beijing, People’s Republic of China; 8Institute of Rheumatology and Immunology, Hangzhou Medical College, Zhejiang, 310014, People’s Republic of China; 9Zhejiang Provincial Key Laboratory of Traditional Chinese Medicine Cultivation for Arthritis Diagnosis and Treatment, Zhejiang, 310014, People’s Republic of China

Correspondence: Zhenhua Ying, Email yingzh2021@163.com Chen Li, Email casio1981@163.com

Abstract: Palmoplantar pustulosis (PPP) is a chronic inflammatory skin disease with recurrent erythema, scales, and sterile pustules on the palms and soles. Treating PPP in children is difficult due to limited effective therapies, especially as there’s a lack of data on upadacitinib use in children under 12.This article reports a pediatric PPP case. The patient had severe, recurring rashes that affected daily activities. Treated with upadacitinib for two months, she showed a significant therapeutic response.

Keywords: palmoplantar pustulosis, children, treatment, upadacitinib